{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-21-048256","form_type":"8-K","ticker":"CELU","cik":"0001752828","company_name":"Celularity Inc","filed_at":"2021-09-15T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.491109+00:00","generated_at":"2026-06-29T03:35:30.886004+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Celularity appoints Andrew Pecora as President; Hariri remains CEO and Chairman","bullets":["Andrew Pecora named President effective Sept 15, 2021, replacing Robert Hariri who stays CEO/Chairman.","Pecora receives $900K base salary, 60% target bonus, and a signing bonus of $1.2M paid in four installments.","Granted option to purchase 2,469,282 shares, vesting upon achievement of share price targets over up to five installments.","Pecora previously served as consultant and on Sci Advisory Board; related party transactions with COTA and son's employment disclosed.","Employment at-will; severance includes nine months' salary (or 12 months after change in control) and COBRA coverage."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-21-048256","json":"https://secwatch.observer/filing/0001213900-21-048256.json","markdown":"https://secwatch.observer/filing/0001213900-21-048256.md","text":"https://secwatch.observer/filing/0001213900-21-048256.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1752828/000121390021048256/0001213900-21-048256-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1752828/000121390021048256/ea147489-8k_celularity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T03:35:30.886004+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"45a2178f85","claim":"Andrew L. Pecora, M.D. was appointed as President at Celularity Inc.","evidence_excerpt":"appointed Andrew L. Pecora, M.D., as President of the Company effective September 15, 2021, replacing Robert J. Hariri, M.D., Ph.D., in this role as of such date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1752828/000121390021048256/0001213900-21-048256-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"96a5e12ad1","claim":"Robert J. Hariri, M.D., Ph.D. changed role as Chief Executive Officer and Chairman of the Board at Celularity Inc.","evidence_excerpt":"appointed Andrew L. Pecora, M.D., as President of the Company effective September 15, 2021, replacing Robert J. Hariri, M.D., Ph.D., in this role as of such date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1752828/000121390021048256/0001213900-21-048256-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"replaced as President"},{"label":"Role","value":"Chief Executive Officer and Chairman of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}